Bright Futures Wealth Management LLC. Sells 1,931 Shares of Johnson & Johnson (NYSE:JNJ)

Bright Futures Wealth Management LLC. lowered its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 55.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,575 shares of the company's stock after selling 1,931 shares during the period. Bright Futures Wealth Management LLC.'s holdings in Johnson & Johnson were worth $238,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. AMF Tjanstepension AB increased its stake in shares of Johnson & Johnson by 14.2% in the third quarter. AMF Tjanstepension AB now owns 425,261 shares of the company's stock worth $68,985,000 after acquiring an additional 52,997 shares during the last quarter. Alpha Financial Partners LLC acquired a new position in Johnson & Johnson in the 3rd quarter worth about $209,000. Wealth Group Ltd. purchased a new stake in shares of Johnson & Johnson during the 3rd quarter worth about $213,000. Swedbank AB lifted its holdings in shares of Johnson & Johnson by 5.3% during the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company's stock valued at $358,980,000 after buying an additional 111,570 shares during the last quarter. Finally, Schaper Benz & Wise Investment Counsel Inc. WI grew its stake in shares of Johnson & Johnson by 1.8% in the 3rd quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 97,483 shares of the company's stock valued at $15,798,000 after buying an additional 1,768 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Remove Ads

Johnson & Johnson Stock Performance

JNJ stock traded up $2.67 during midday trading on Friday, hitting $162.35. The stock had a trading volume of 12,540,171 shares, compared to its average volume of 9,073,381. The firm has a market capitalization of $390.87 billion, a price-to-earnings ratio of 24.41, a P/E/G ratio of 2.53 and a beta of 0.52. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a 50-day simple moving average of $148.93 and a 200 day simple moving average of $155.90. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm's revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.29 earnings per share. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.06%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson's payout ratio is 74.59%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Barclays lifted their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a research note on Tuesday, January 28th. Stifel Nicolaus decreased their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a report on Thursday, January 23rd. Bank of America cut their target price on Johnson & Johnson from $160.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, January 23rd. Citigroup decreased their price target on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a research note on Wednesday, December 11th. Finally, Argus raised Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $170.67.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.